379 related articles for article (PubMed ID: 33187478)
1. Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data.
Murray J; Hilbig A; Soe TT; Ei WLSS; Soe KP; Ciglenecki I
BMC Infect Dis; 2020 Nov; 20(1):842. PubMed ID: 33187478
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
3. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
[TBL] [Abstract][Full Text] [Related]
4. Oral valganciclovir in human immunodeficiency virus-positive patients suffering from cytomegalovirus retinitis at a tertiary care hospital in North India.
Markan A; Gupta N; Dogra M; Sharma A; Singh R
Indian J Ophthalmol; 2022 Jul; 70(7):2472-2475. PubMed ID: 35791137
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study.
Teerawattananon K; Iewsakul S; Yenjitr C; Ausayakhun S; Yenjitr W; Mugford M; Teerawattananon Y
Pharmacoeconomics; 2007; 25(5):413-28. PubMed ID: 17488139
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis.
Choopong P; Vivittaworn K; Konlakij D; Thoongsuwan S; Pituksung A; Tesavibul N
BMC Infect Dis; 2016 Apr; 16():164. PubMed ID: 27090644
[TBL] [Abstract][Full Text] [Related]
7. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela.
Arevalo JF; Garcia RA; Mendoza AJ
Eur J Ophthalmol; 2005; 15(5):610-8. PubMed ID: 16167292
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
Freeman RB
Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen.
Teoh SC; Ou X; Lim TH
Ophthalmology; 2012 Mar; 119(3):588-95. PubMed ID: 22137552
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir: an advance in cytomegalovirus therapeutics.
Cocohoba JM; McNicholl IR
Ann Pharmacother; 2002 Jun; 36(6):1075-9. PubMed ID: 12022911
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.
Segarra-Newnham M; Salazar MI
Pharmacotherapy; 2002 Sep; 22(9):1124-8. PubMed ID: 12222548
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of cytomegalovirus retinitis-related retinal detachment surgery in acquired immunodeficiency syndrome patients in an Asian population.
Wong JX; Wong EP; Teoh SC
BMC Ophthalmol; 2014 Nov; 14():150. PubMed ID: 25429876
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results.
Cheng YC; Kang EY; Hwang YS; Hsiao CH
Sci Rep; 2021 Feb; 11(1):3105. PubMed ID: 33542372
[TBL] [Abstract][Full Text] [Related]
15. CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar.
Tun N; London N; Kyaw MK; Smithuis F; Ford N; Margolis T; Drew WL; Lewallen S; Heiden D
J Int AIDS Soc; 2011 Aug; 14():41. PubMed ID: 21843351
[TBL] [Abstract][Full Text] [Related]
16. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
Martin DF; Kuppermann BD; Wolitz RA; Palestine AG; Li H; Robinson CA
N Engl J Med; 1999 Apr; 340(14):1063-70. PubMed ID: 10194235
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus retinitis and AIDS in Edinburgh.
Dhillon B; Maclean H; Eddyshaw D; Cheong I; Flegg P; Brettle R
Int J STD AIDS; 1993; 4(6):339-41. PubMed ID: 8305575
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment.
Prescrire Int; 2003 Aug; 12(66):133-5. PubMed ID: 12906021
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir hydrochloride.
Am J Health Syst Pharm; 2001 Dec; 58(23):2246-7. PubMed ID: 11763801
[No Abstract] [Full Text] [Related]
20. Prevalence and clinical management of cytomegalovirus retinitis in AIDS patients in Shanghai, China.
Shi Y; Lu H; He T; Yang Y; Liu L; Zhang R; Zheng Y; Shen Y; Zhang Y; Zhang Z
BMC Infect Dis; 2011 Nov; 11():326. PubMed ID: 22115120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
